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A McLenaghan, E Paxton, A Polet, C Thompson, C M Dayan
Summary 
Background Lifestyle changes soon after diagnosis might improve outcomes in patients with type 2 diabetes mellitus, 
but no large trials have compared interventions. We investigated the eﬀ ects of diet and physical activity on blood 
pressure and glucose concentrations.
Methods We did a randomised, controlled trial in southwest England in adults aged 30–80 years in whom type 2 
diabetes had been diagnosed 5–8 months previously. Participants were assigned usual care (initial dietary consultation 
and follow-up every 6 months; control group), an intensive diet intervention (dietary consultation every 3 months 
with monthly nurse support), or the latter plus a pedometer-based activity programme, in a 2:5:5 ratio. The primary 
endpoint was improvement in glycated haemoglobin A1c (HbA1c) concentration and blood pressure at 6 months. 
Analysis was done by intention to treat. This study is registered, number ISRCTN92162869.
Findings Of 593 eligible individuals, 99 were assigned usual care, 248 the diet regimen, and 246 diet plus activity. Outcome 
data were available for 587 (99%) and 579 (98%) participants at 6 and 12 months, respectively. At 6 months, glycaemic 
control had worsened in the control group (mean baseline HbA1c percentage 6·72, SD 1·02, and at 6 months 6·86, 1·02) 
but improved in the diet group (baseline-adjusted diﬀ erence in percentage of HbA1c –0·28%, 95% CI –0·46 to –0·10; 
p=0·005) and diet plus activity group (–0·33%, –0·51 to –0·14; p<0·001). These diﬀ erences persisted to 12 months, 
despite less use of diabetes drugs. Improvements were also seen in bodyweight and insulin resistance between the 
intervention and control groups. Blood pressure was similar in all groups.
Interpretation An intensive diet intervention soon after diagnosis can improve glycaemic control. The addition of 
an activity intervention conferred no additional beneﬁ t.
Funding Diabetes UK and the UK Department of Health.
Introduction
Increased physical activity and dietary management 
implemented by health-care professionals is funda mental 
to initial treatment of type 2 diabetes mellitus and is 
recommended by international consensus.1,2 Meta-analyses 
of exercise and diet studies have concluded that 
concentrations of glycated haemo globin A1c (HbA1c) can be 
lowered by aerobic and resistance exercise and by dietary 
intervention, by 0·6–0·8%3–5 and 0·5%, respectively.6,7 
Most studies inclu ded in these meta-analyses, however, 
were of short duration, involved small numbers of patients 
overall, and of these only a few had newly diagnosed type 2 
diabetes. Control of blood pressure prevents microvascular 
and macro vascular complications in patients with type 2 
diabetes,8 but only two studies have speciﬁ cally assessed 
the independent eﬀ ects of exercise on blood pressure in 
these patients.9,10 Only six small studies have assessed 
whether the eﬀ ects of exercise plus dietary intervention on 
concentrations of HbA1c or other metabolic markers, such 
as blood pressure, in type 2 diabetes were additional to 
those of dietary interventions alone.9–14 
Patients with newly diagnosed type 2 diabetes in the 
UK are oﬀ ered dietary advice on a one-to-one basis, 
attendance at an education day, or both, but few health-
care workers are trained to give appropriate advice 
about activity and, therefore, information is frequently 
general rather than tailored to individual patients’ 
needs. To increase levels of activity in patients with 
type 2 diabetes, clinical services would need to be 
restructured and health-care workers retrained. Before 
making such changes, however, an additional beneﬁ t of 
activity over current dietary advice would need to be 
clearly shown.
The aim of the Early Activity in Diabetes (Early ACTID) 
trial was to investigate whether increased physical activity 
would have eﬀ ects on glycaemia, blood pressure, lipid pro-
ﬁ le, insulin resistance, and insulin secretion additional to 
those yielded by an intensiﬁ ed dietary intervention or usual 
care in individuals with newly diagnosed type 2 diabetes.
Methods
Patients
The study was a multicentre, parallel-group, randomised, 
controlled trial. The study was approved by the Bath 
Research Ethics Committee (05/Q2001/5), and all 
participants provided written informed consent.
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We recruited patients between December, 2005, and 
September, 2008, by searching the records databases of 
217 general practices in southwest England, and of 
community-based education programmes, and by direct 
advertising. Eligible patients had been diagnosed within 
the previous 5–8 months and were older than 30 years 
at diagnosis. Exclusion criteria were age older than 
80 years, HbA1c concentration greater than 10%, blood 
1634 individuals identiﬁed or replied to 
advertisements
712 eligible for face-to-face screening
700 screened  
593 randomised 
326 excluded
207 diagnosed >8 months previously
56 BMI <25 kg/m²
21 unable to exercise
17 no diabetes or had type 1 diabetes
8 unable to provide informed consent
10 aged <30 or >80 years
4 outside of geographical catchment area
2 at risk of pregnancy
1 other health issues
596 withdrew (decided not to continue)         
 
8 excluded (did not attend visits)
4 withdrew (decided not to continue) 
 
103 excluded
4 diagnosed >8 months previously
13 did not attend visits
14 BMI <25 kg/m²
8 unable to exercise
15 no diabetes or had type 1 diabetes
1 pregnant
11 other health issues
28 time or work commitments
2 no reason given
4 diabetes control too poor
2 BP too high
1 died
4 withdrew (decided not to continue)          
99 assigned
usual care   
248 assigned
intensive
dietary support   
247 available for 
analysis of 
primary endpoint 
at 6 months
246 assigned
intensive
dietary support
and activity    
93 available for
analysis of primary
endpoint at 
12 months     
1 lost to follow-up
(new diagnosis)  
1 lost to follow-up
(died) 
2 lost to follow-up
1 no reason given
1 new diagnosis   
2 lost to follow-up
1 time/work 
commitment
1 moved away   
3 lost to follow-up
(time/work
commitments)  
1 withdrew 
(dissatisﬁed with 
usual care)
2 withdrew (wished
to return to family
doctor care)   
97 available for
analysis of
primary endpoint
at 6 months   
1 lost to follow-up
(time/work 
commitments) 
246 available for
analysis of
primary endpoint
at 12 months    
243 available for
analysis of
primary endpoint
at 6 months    
240 available for
analysis of
primary endpoint
at 12 months    
1 withdrew (wished
to return to family
doctor care)   
Figure: Trial proﬁ le
BMI=body-mass index. BP=blood pressure.
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pressure higher than 180/100 mm Hg, LDL cholesterol 
concentration higher than 4 mmol/L, body-mass index 
(BMI) lower than 25 kg/m², weight greater than 180 kg, 
use of weight-loss drugs, taking a sulphonylurea at the 
maximum dose, unstable angina, a myocardial 
infarction within the previous 3 months, inability to 
increase physical activity, and pregnancy or planning to 
become pregnant.
Patients were initially screened by a research nurse on 
the telephone and potentially eligible individuals were 
invited to attend a face-to-face assessment to conﬁ rm 
eligibility at least 2 weeks before randomisation (visit 1), 
where nurses involved in the study obtained informed 
consent, recorded clinical history, and did a physical 
examination. Participants returned to do a 1-mile walk test 
to assess ﬁ tness (visit 2)15 and again to remeasure values 
for baseline variables (visit 3). Between baseline and 
randomisation all patients were seen by a study doctor 
(visit 4). The study was done in ﬁ ve secondary care National 
Health Service trusts: Taunton and Somerset NHS 
Foundation Trust, University Hospitals Bristol NHS 
Foundation Trust, North Bristol NHS Trust, Gloucester-
shire Hospitals NHS Trust, and Weston Area Health 
NHS Trust. 
Randomisation
Randomisation was done according to computer-
generated allocation. Patients were assigned, in a 
2:5:5 ratio, to usual care, an intensive diet intervention, 
or the intensive diet intervention plus activity. Allocations 
remained concealed by the trial coordinator until patients 
attended visit 4, when they saw a dietitian who telephoned 
to get the next code. Allocation was stratiﬁ ed by centre 
and minimised by age, sex, ﬁ tness, route into the study 
and blood pressure. Dietitians, nurses, and patients were 
aware of allocation, but doctors were not. All assessments 
were done by nurses.
Procedures
Usual care consisted of standard dietary and exercise 
advice after randomisation and at the end of the 
study, with reviews by a study doctor and nurse at 
baseline and at 6 and 12 months. This group was used 
as the control.
The intensive diet intervention was aimed at enabling 
patients to lose 5–10% of their initial bodyweight and to 
maintain this loss throughout the study. The intervention 
was based on the Diabetes UK dietary guidelines16 and 
the Balance of Good Health leaﬂ et from the UK Food 
Standards Agency,17 and used goal-oriented motivational 
interviews.18 Guidance was given on how many portions 
of each food group to choose and participants were 
speciﬁ cally encouraged to choose foods in the lower 
ranges of energy density, fat content, and glycaemic 
index. The diet was not prescriptive; goals were 
negotiated individually with each participant during 
their ﬁ rst session with the dietitian and were reviewed at 
each visit. Participants saw the dietitian for 1 h at 
randomisation and for 30 min at each of 3, 6, 9, and 
12 months. Dietary advice and goal setting was reinforced 
by nine 30 min appointments with study nurses—
roughly one every 6 weeks over the course of the study. 
During these visits the nurse spent 15 min discussing 
diet and another 15 min discussing any other issues the 
patient wished to raise.
Patients in the intensive diet and physical activity 
group received the same dietary intervention as those in 
the intensive diet group. Additionally, participants were 
asked to do at least 30 min brisk walking on at least 
5 days per week, in line with national guidelines for 
physical activity, in addition to current levels of physical 
activity. Each patient was given a pedometer (Digiwalker 
CW200, Yamax, Japan) and a folder containing 
motivating literature and pages for recording daily 
physical activity (pedometer readings). Activity targets 
were gradually increased over 5 weeks then maintained 
for the remainder of the study. During the nurse 
appointments 15 min was spent addressing dietary 
issues and 15 min discussing the diary entries for 
physical activity to keep the total contact time the same 
as in the intensive diet intervention group.
Management of type 2 diabetes, blood pressure, and 
lipid proﬁ le was undertaken by the study team for the 
Usual care
(n=99)
Intensive dietary 
intervention
(n=248)
Intensive dietary 
intervention and 
activity (n=246)
Male sex 62 (63%) 158 (64%) 165 (66%)
Mean (SD) age (years) 59·5 (11·1) 60·1 (10·2) 60·0 (9·7)
White 96 (97%) 239 (96%) 232 (94%)
Married or with long-term partner 71 (72%) 188 (76%) 192 (78%)
Smoker 8 (8%) 24 (9·6%) 16 (7%)
Median (IQR) time since diagnosis (days) 185 (148–232) 186 (152–225) 194 (151–233)
Oral hypoglycaemic agents
Metformin 32 (32%) 91 (37%) 84 (34%)
Sulphonylurea 7 (7%) 20 (8%) 23 (9%)
Thiazolidinedione 2 (2%) 1 (0·4%) 4 (2%)
Total 35 (35%) 98 (40%) 95 (39%)
Antihypertensive agents
Renin-angiotensin agent 47 (47%) 132 (53%) 112 (46%)
Thiazide diuretic 24 (24%) 57 (23%) 52 (21%)
β blocker 20 (20%) 47 (19%) 40 (16%)
Calcium-channel blocker 14 (14%) 53 (21%) 46 (19%)
Other 7 (7%) 14 (6%) 14 (6%)
Total 58 (59%) 168 (68%) 139 (57%)
Lipid-lowering drugs
Statin 63 (64%) 156 (63%) 148 (60%)
Fibrate 0 1 (0·4%) 1 (0·4%)
Other 0 12 (5%) 3 (1%)
Total 63 (64%) 162 (65%) 150 (61%)
Antiobesity agents 0 0 0
Table 1: Baseline characteristics
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period of the trial. Any changes in treatment of these 
features were made by a doctor unaware of treatment 
allocation and according to a strict trial protocol to keep 
the risk of performance bias to a minimum. During the 
ﬁ rst 6 months of the study, diabetes treatment was only 
changed if fasting blood glucose concentration rose to 
more than 12·0 mmol/L, patients became symptomatic, 
or if blood pressure was higher than 160/90 mm Hg at 
any visit. During the second 6 months, patients were 
treated as appropriate to maintain the following targets: 
HbA1c concentration lower than 7·4%, blood pressure 
lower than 140/85 mm Hg, total cholesterol concentra-
tion lower than 4·0 mmol/L, HDL cholesterol concen -
tra tion higher than 1·0 mmol/L, LDL cholesterol 
con cen tration lower than 2·0 mmol/L, and con cen-
tration of triglycerides lower than 2·0 mmol/L. All 
measurements were done in one laboratory with 
standard techniques. Insulin resistance and insulin 
secretion were measured by homoeostasis model 
assessment.19 Features of body composition (weight, 
percentage of fat, and bioimpedance) and waist and hip 
circumferences were measured according to standard 
procedures. Physical activity was assessed by 
accelerometry20 at baseline and at 6 and 12 months.
Statistical analysis
The primary endpoint consisted of improvements in 
HbA1c concentration and blood pressure 6 months after 
randomisation. Secondary outcomes were changes 
in insulin resistance and insulin secretion, lipid pro-
ﬁ le, physical activity, body composition, waist and 
hip circumference, and medication use at 6 and 
12 months.
The study was powered to detect diﬀ erences in HbA1c 
concentration and blood pressure between the intensive 
diet and the intensive diet plus activity groups 6 months 
after randomisation. We assumed an SD of 1·87% for 
HbA1c, on the basis of reported values among patients 
with type 2 diabetes,21 and sought a target diﬀ erence of 
0·5%, which equates to an eﬀ ect size of 0·27 SD. For 
blood pressure this eﬀ ect size equates to 4–5 mm Hg 
systolic and 2–3 mm Hg diastolic,22 which would be 
deemed clinically important in practice. The original 
target sample size of 750 was based on 90% power, but 
was revised after 378 patients had been recruited, 
because retention was better but recruitment was slower 
than expected. The ﬁ nal target sample size, therefore, 
was 546 participants (216 in each of study intervention 
arms and 86 in the control arm), which provided 
Mean (SD) Between-group 
diﬀ erences at 
6 months (95% CI)*
p Between-group 
diﬀ erences at 
12 months (95% CI)*
p
Baseline 6 months 12 months
HbA1c (%) 
Usual care 6·72 (1·02) 6·86 (1·02) 6·81 (0·91) ·· ·· ·· ··
Diet 6·64 (0·93) 6·57 (1·06) 6·55 (0·95) ·· ·· ·· ··
Diet and activity 6·69 (0·99) 6·60 (1·00) 6·65 (0·93) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· –0·05 (–0·18 to 0·09) 0·51 0·06 (–0·08 to 0·19) 0·43
Diet vs usual care ·· ·· ·· –0·28 (–0·46 to – 0·10) 0·0049† –0·26 (–0·44 to –0·08) 0·005
Diet and activity vs usual care ·· ·· ·· –0·33 (–0·51 to –0·14) 0·0009† –0·21 (–0·39 to –0·02) 0·027
Systolic BP (mm Hg)
Usual care 135 (14) 134 (13) 133 (12) ·· ·· ·· ··
Diet 133 (15) 133 (15) 132 (14) ·· ·· ·· ··
Diet and activity 133 (15) 133 (15) 133 (15) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 1·14 (–0·88 to 3·15) 0·27 1·27 (–0·73 to 3·26) 0·21
Diet vs usual care ·· ·· ·· 0·02 (–2·65 to 2·68) 1† –0·04 (–2·76 to 2·68) 0·98
Diet and activity vs usual care ·· ·· ·· 1·15 (–1·53 to 3·83) 0·80† 1·22 (–1·51 to 3·96) 0·38
Diastolic BP (mm Hg)
Usual care 80 (9) 79 (8) 79 (10) ·· ·· ·· ··
Diet 79 (8) 79 (9) 79 (8) ·· ·· ·· ··
Diet and activity 79 (8) 79 (8) 79 (9) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·39 (–0·83 to 1·61) 0·53 0·36 (–0·91 to 1·64) 0·58
Diet vs usual care ·· ·· ·· 0·43 (–1·20 to 2·06) 1† 0·44 (–1·30 to 2·18) 0·62
Diet and activity vs usual care ·· ·· ·· 0·82 (–0·82 to 2·45) 0·65† 0·80 (–0·95 to 2·56) 0·37
HBA1c=glycated haemoglobin A1c. BP=blood pressure.*Adjusted for male or female sex, route into study (general practice, education centre, or responding to an 
advertisement), age (continuous), ﬁ tness (low [if  maximum oxygen consumption poor or very poor on normative data] or high [if  maximum oxygen consumption fair, 
good, excellent, or superior on normative data]), study centre (Taunton, North Bristol, South Bristol, or Cheltenham and Gloucester), baseline HbA1c (continuous), and blood 
pressure (<120/80 mm Hg, 120/80–139/89 mm Hg, or ≥140/90 mm Hg). †Bonferroni correction is p’=min (1, kp), where k=number of 1 df tests.
Table 2: Primary outcomes at 6 and 12 months
For the trial protocol see http://
jcrubristol.org.uk/EA/ACTID%20
Protocol/Forms/AllItems.aspx
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80% power with a 5% two-sided α to detect the above 
diﬀ erences and a diﬀ erence of 0·4 SD in outcomes 
when comparing the intensive diet or intensive diet plus 
activity interventions with usual care, allowing for 5% of 
data missing.
We used descriptive statistics and tests to assess 
individuals randomised in relation to those assessed for 
eligibility but not randomised, and we used descriptive 
statistics alone to compare the randomised groups at 
baseline.23 The primary outcome was assessed by 
intention to treat without imputation. We used 
multivariable linear regression to compare the intensive 
diet and intensive diet plus activity groups for each of the 
primary outcomes at 6 months, with adjustment for the 
baseline value of the outcome, study centre, and 
minimisation variables. Additionally, we adjusted 
secondary models for any variables showing imbalance 
at baseline. Similar regression models were used to 
investigate secondary comparisons of each intervention 
group versus usual care for the three primary outcomes, 
with Bonferroni correction, secondary outcomes, with 
linear or logistic regression models dependent on 
outcome type, and primary and secondary outcomes at 
12 months of follow-up. Use of drugs for the treatment of 
diabetes, hypertension, and lipid regulation were 
investigated with logistic (medi cation vs no medication) 
Mean (SD) Between-group 
diﬀ erences at 
6 months (95% CI)*
p Between-group 
diﬀ erences at 
12 months (95% CI)*
p
Baseline 6 months 12 months
Biochemical measures
Total cholesterol (mmol/L)
Usual care 4·44 (1·07) 4·51 (0·88) 4·36 (0·94) ·· ·· ·· ··
Diet 4·34 (0·87) 4·33 (0·89) 4·22 (0·87) ·· ·· ·· ··
Diet and activity 4·33 (0·95) 4·36 (0·96) 4·28 (0·95) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·04  (–0·08 to 0·16) 0·49 0·07 (–0·08 to 0·21) 0·38
Diet vs usual care ·· ·· ·· –0·13 (–0·29 to 0·02) 0·09 –0·11 (–0·31 to 0·08) 0·26
Diet and activity vs usual care ·· ·· ·· –0·09 (–0·25 to ·006) 0·25 –0·05 (–0·24 to 0·15) 0·64
HDL cholesterol (mmol/L) 
Usual care 1·34 (0·33) 1·28 (0·32) 1·34 (0·40) ·· ·· ·· ··
Diet 1·28 (0·33) 1·28 (0·32) 1·28 (0·32) ·· ·· ·· ··
Diet and activity 1·28 (0·34) 1·33 (0·38) 1·31 (0·35) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·05 (0·01 to 0·09) 0·016 0·02 (–0·02 to 0·06) 0·25
Diet vs usual care ·· ·· ·· 0·04 (–0·01 to 0·10) 0·097 –0·02 (–0·08 to 0·03) 0·38
Diet and activity vs usual care ·· ·· ·· 0·09 (0·04 to 0·15) 0·0006 0·00 (–0·06 to 0·05) 0·98
LDL cholesterol (mmol/L)
Usual care 2·36 (0·90) 2·41 (0·76) 2·24 (0·81) ·· ·· ·· ··
Diet 2·30 (0·79) 2·29 (0·78) 2·17 (0·71) ·· ·· ·· ··
Diet and activity 2·29 (0·77) 2·33 (0·81) 2·22 (0·76) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·04 (–0·06 to 0·15) 0·40 0·07 (–0·06 to 0·19) 0·29
Diet vs usual care ·· ·· ·· –0·10 (–0·25 to 0·04) 0·14 –0·05 (–0·22 to 0·11) 0·51
Diet and activity vs usual care ·· ·· ·· –0·06 (–0·20 to 0·08) 0·40 0·01 (–0·15 to 0·17) 0·89
Triglycerides (mmol/L) 
Usual care 1·68 (1·04) 1·81 (1·13) 1·71 (0·97) ·· ·· ·· ··
Diet 1·71 (0·89) 1·67 (0·94) 1·74 (1·35) ·· ·· ·· ··
Diet and activity 1·69 (0·91) 1·50 (0·76) 1·63 (1·26) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· –0·14 (–0·26 to –0·03) 0·016 –0·10 (–0·30 to 0·09) 0·31
Diet vs usual care ·· ·· ·· –0·16 (–0·31 to 0·00) 0·044 0·01 (–0·25 to 0·27) 0·94
Diet and activity vs usual care ·· ·· ·· –0·30 (–0·46 to –0·15) 0·0002 –0·09 (–0·36 to 0·17) 0·50
Insulin resistance (log HOMA-IR)
Usual care 1·62 (0·57) 1·71 (0·65) 1·67 (0·66) ·· ·· ·· ··
Diet 1·60 (0·74) 1·44 (0·64) 1·44 (0·66) ·· ·· ·· ··
Diet and activity 1·65 (0·91) 1·49 (0·62) 1·53 (0·62) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·02 (–0·06 to 0·11) 0·57 0·08 (–0·01 to 0·17) 0·084
Diet vs usual care ·· ·· ·· –0·26 (–0·37 to –0·15) <0·0001 –0·24 (–0·37 to –0·12) 0·0001
Diet and activity vs usual care ·· ·· ·· –0·24 (–0·35 to –0·13) <0·0001 –0·16 (–0·29 to –0·04) 0·011
(Continues on next page)
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and linear (daily prescribed dose as percentage of the 
maximum) regression models. Finally, we did subgroup 
analyses by including interaction terms in the following 
regression models: each of the primary outcomes at 
6 months by sex, baseline age, HbA1c concentration, 
physical activity, and time since diagnosis; BMI at 
6 months and baseline; and insulin resistance at 6 months 
by baseline BMI; and insulin resistance at 6 months by 
baseline insulin resistance. This study is registered, 
number ISRCTN92162869.
Role of the funding sources
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
Of 1634 patients initially screened by telephone, 712 were 
eligible for face-to-face screening and 593 were enrolled 
in the study (ﬁ gure). Follow-up was completed in 
September, 2009. The most frequent reasons for exclusion 
were diagnosis more than 8 months previously (33%), 
BMI lower than 25 kg/m² (11%), and a misdiagnosis of 
type 2 diabetes (5%). The characteristics of participants 
entered into the trial were similar to those of the 
119 people who were assessed but not randomised.
Characteristics of enrolled patients in all groups were 
similar at baseline (table 1). Additional baseline values 
for outcome measures are shown in table 2 and table 3. 
Glycaemic control was good in most patients across all 
Mean (SD) Between-group 
diﬀ erences at 
6 months (95% CI)*
p Between-group 
diﬀ erences at 
12 months (95% CI)*
p
Baseline 6 months 12 months
(Continued from previous page)
Anthropometric measures
Weight  (kg) 
Usual care 93·9 (19·0) 94·2 (20·0) 93·5 (18·1) ·· ·· ·· ··
Diet 90·2 (16·7) 88·5 (16·9) 88·7 (17·3) ·· ·· ·· ··
Diet and activity 91·1 (16·9) 88·4 (16·0) 88·7 (16·0) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·08 (–0·53 to 0·68) 0·81 0·15 (–0·65 to 0·95) 0·71
Diet vs usual care ·· ·· ·· –2·28 (–3·08 to –1·48) <0·0001 –2·41 (–3·49 to –1·32) <0·0001
Diet and activity vs usual care ·· ·· ·· –2·21 (–3·01 to –1·40) <0·0001 –2·25 (–3·35 to –1·16) <0·0001
Waist circumference (cm) 
Usual care 108 (12) 108 (13) 108 (12) ·· ·· ·· ··
Diet 106 (13) 104 (12) 104 (13) ·· ·· ·· ··
Diet and activity 107 (12) 104 (13) 104 (12) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·39 (–0·54 to 1·32) 0·41 0·26 (–0·66 to 1·17) 0·578
Diet vs usual care ·· ·· ·· –2·70 (–3·94 to –1·47) <0·0001 –2·80 (–4·05 to –1·55) <0·0001
Diet and activity vs usual care ·· ·· ·· –2·31 (–3·55 to –1·07) 0·0003 –2·54 (–3·80 to –1·28) <0·0001
Activity
Moderate to vigorous activity (min per day)
Usual care 26 (20) 24 (20) 26 (23) ·· ·· ·· ··
Diet 26 (20) 29 (24) 27 (24) ·· ·· ·· ··
Diet and activity 23 (17) 33 (21) 31 (25) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 5·47 (2·03 to 8·91) 0·002 4·70 (0·82 to 8·58) 0·018
Diet vs usual care ·· ·· ·· 3·63 (–0·94 to 8·20) 0·12 0·92 (–4·29 to 6·13) 0·73
Diet and activity vs usual care ·· ·· ·· 9·10 (4·45 to 13·75) 0·0001 5·62 (0·36 to 10·87) 0·036
HOMA-IR=homoeostasis model assessment for insulin resistance. *Adjusted for male or female sex, route into study (general practice, education centre, or responding to an 
advertisement), age (continuous), ﬁ tness (low [if  maximum oxygen consumption poor or very poor on normative data] or high [if  maximum oxygen consumption fair, 
good, excellent, or superior on normative data]), study centre (Taunton, North Bristol, South Bristol, or Cheltenham and Gloucester), baseline glycated haemoglobin A1c 
(continuous), and blood pressure (<120/80 mm Hg, 120/80–139/89 mm Hg, or ≥140/90 mm Hg).
Table 3: Secondary outcomes at 6 and 12 months
Number (%) of patients
Baseline (n=220) 6 months (n=221) 12 months (n=221)
Sedentary (<5000 steps per day) 76 (34·5%) 40 (18·1%) 40 (18·1%)
Low active (5000–7499 steps per day) 81 (36·8%) 69 (31·2%) 71 (32·1%)
Somewhat active (7500–9999 steps per day) 43 (19·5%) 72 (32·6%) 70 (31·7%)
Active (≥10 000 steps per day) 20 (9·1%) 40 (18·1%) 40 (18·1%)
Table 4: Number of participants in the intensive diet and activity group in each activity category at 
baseline and at 6 and 12 months
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groups, with 68% having HbA1c below 7·0%, which is 
within the expected range for the early timepoint 
after diagnosis.
In the intervention groups mean attendance and mean 
total contact times were similar: 13·4 (SD 2·2) visits and 
448 (SD 80) min in the intensive diet intervention group 
and 13·2 (SD 2·5) visits and 459 (SD 94) min in the 
intensive diet intervention and activity group. Patients 
in the latter group had increased their physical activity 
signiﬁ cantly more at 6 months than had those in the 
other two groups (table 3), and this diﬀ erence was 
maintained at 12 months. Almost 90% of participants in 
the intensive diet intervention and activity group 
recorded pedometer counts daily (mean 6·7, SD 0·3, 
days per week). The mean number of steps taken daily 
by patients in the intensive diet plus activity group had 
increased by 17% at 6 months from 6399 (SD 3056) 
to 7680 (SD 2818), and this level of activity was 
maintained at 12 months (7621, SD 2778). The number 
of patients overall who were active nearly doubled from 
baseline to 12 months (table 4). Primary outcome data 
were collected for at least 583 (99%) and 579 (98%) of 
participants at 6 months and 12 months of follow-up, 
respectively (ﬁ gure, table 2).
Mean (SD) Between-group 
diﬀ erences at 
6 months (95% CI)*
p Between-group 
diﬀ erences at 
12 months (95% CI)*
p
Baseline 6 months 12 months
Biochemical measures
Log fasting glucose (mmol/L)
Usual care 2·00 (0·19) 2·05 (0·23) 2·04 (0·27) ·· ·· ·· ··
Diet 1·99 (0·50) 1·95 (0·20) 1·95 (0·20) ·· ·· ·· ··
Diet and activity 2·00 (0·20) 1·98 (0·20) 1·99 (0·20) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·02 (–0·01 to 0·05) 0·12 0·03 (0 to 0·07) 0·06
Diet vs usual care ·· ·· ·· –0·11 (–0·15 to –0·07) <0·0001 –0·10 (–0·15 to –0·05) <0·0001
Diet and activity vs usual care ·· ·· ·· –0·09 (–0·13 to –0·04) <0·0001 –0·06 (–0·11 to –0·02) 0·01
Log fasting insulin (pmol/L)
Usual care 2·74 (0·52) 2·78 (0·55) 2·74 (0·57) ·· ·· ·· ··
Diet 2·72 (0·54) 2·61 (0·56) 2·60 (0·60) ·· ·· ·· ··
Diet and activity 2·76 (0·55) 2·63 (0·57) 2·66 (0·57) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· –0·01 (–0·06 to 0·05) 0·83 0·04 (–0·02 to 0·11) 0·22
Diet vs usual care ·· ·· ·· –0·15 (–0·23 to –0·07) 0·0002 –0·14 (–0·23 to –0·06) 0·001
Diet and activity vs usual care ·· ·· ·· –0·16 (–0·23 to –0·08) <0·0001 –0·10 (–0·19 to –0·01) 0·022
Log insulin secretion (HOMA–B)
Usual care 4·41 (0·60) 4·36 (0·59) 4·34 (0·68) ·· ·· ·· ··
Diet 4·42 (0·82) 4·39 (0·62) 4·36 (0·65) ·· ·· ·· ··
Diet and activity 4·43 (0·64) 4·35 (0·64) 4·36 (0·66) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· –0·04 (–0·11 to 0·04) 0·35 0·00 (–0·09 to 0·08) 0·96
Diet vs usual care ·· ·· ·· 0·05 (–0·05 to 0·15) 0·32 0·03 (–0·08 to 0·15) 0·58
Diet and activity vs usual care ·· ·· ·· 0·01 (–0·09 to 0·12) 0·78 0·03 (–0·09 to 0·15) 0·61
Anthropometric measures
BMI (kg/m²)
Usual care 32·3 (5·9) 32·4 (6·1) 32·2 (5·6) ·· ·· ·· ··
Diet 31·5 (5·7) 30·9 (5·8) 30·9 (5·9) ·· ·· ·· ··
Diet and activity 31·6 (5·6) 30·7 (5·3) 30·7 (5·3) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·02 (–0·19 to 0·23) 0·86 0·08 (–0·22 vs 0·39) 0·60
Diet vs usual care ·· ·· ·· –0·78 (–1·06 to –0·50) <0·0001 –1·05 (–1·46 vs 0·63) <0·0001
Diet and activity vs usual care ·· ·· ·· –0·76 (–1·05 to –0·48) <0·0001 –0·97 (–1·38 vs –0·55) <0·0001
Bioimpedence (%)
Usual care 36 (9) 36 (9) 36 (8) ·· ·· ·· ··
Diet 35 (8) 34 (9) 34 (8) ·· ·· ·· ··
Diet and activity 35 (8) 34 (9) 33 (9) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 0·01 (–0·45 to 0·48) 0·96 0·15 (–0·37 to 0·68) 0·57
Diet vs usual care ·· ·· ·· –1·26 (–1·88 to –0·64) <0·0001 –1·53 (–2·25 to –0·82) <0·0001
Diet and activity vs usual care ·· ·· ·· –1·25 (–1·87 to –0·62) 0·0001 –1·38 (–2·10 to –0·66) 0·0002
(Continues on next page)
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The intention-to-treat comparison showed no diﬀ erences 
between the intensive diet intervention and the intensive 
diet intervention plus activity for any primary outcomes 
(table 2). Mean HbA1c concentrations were signiﬁ cantly 
lower at 6 and 12 months in patients who received either 
study intervention than in those who received usual care 
(table 2). Eﬀ ect sizes were around 0·3 SDs, and the lower 
95% CI values were roughly equivalent to the prespeciﬁ ed 
target diﬀ erence of –0·5%. The interventions had no eﬀ ect 
on blood pressure. Additional adjustments for variables 
displaying imbalance at baseline did not change these 
results, and all results reported are adjusted only for 
minimisation variables and baseline values of the relevant 
outcome variables. At 12 months of follow-up, primary 
outcomes for the two intervention groups remained 
similar to each other (table 2). The eﬀ ects of both study 
interventions on HbA1c concentrations had weakened 
slightly at 12 months, but remained signiﬁ cant compared 
with usual care.
Diﬀ erences between groups for the secondary outcomes 
were similar to those for the primary outcomes, in that the 
intensive diet intervention and intensive diet intervention 
plus activity groups did not diﬀ er substantially, and 
outcomes in both were better than those in the control 
group for weight, reduction in waist and hip 
circumferences, bioimpedance, and insulin resistance 
(table 3 and table 5). Improvements were also seen in both 
study intervention groups at 6 months in concentrations 
of HDL cholesterol and triglycerides, more so in the 
intensive diet and activity group than in the intensive diet 
alone group, although values were similar at 12 months.
Use of diabetes medications did not diﬀ er between the 
three groups at 6 months, but participants in the usual 
care group were more likely to be taking a diabetes 
medication at 12 months (table 6). Use of drugs to control 
blood pressure and lipid proﬁ le did not diﬀ er at 6 or 
12 months between the three groups (table 6).
The intensive diet intervention plus activity seemed to 
yield better results for HbA1c concentration (p=0·007), 
BMI (p=0·04), and insulin resistance (p<0·001) in 
patients who had high baseline values than for those with 
low baseline values. For systolic blood pressure (p=0·015) 
and, to a lesser degree, diastolic blood pressure (p=0·119), 
this intervention became less eﬀ ective with increasing 
age at baseline.
Discussion
We found that motivation-based, non-supervised diet 
interventions introduced soon after diagnosis of type 2 
diabetes are associated with improvements in glycaemic 
control, use of diabetes medications, weight, waist 
circumference, and insulin resistance compared with 
outcomes in patients receiving usual care. These 
improvements were sustained over a 12-month period. 
The addition of physical activity added no beneﬁ t to the 
use of the intensive diet intervention alone. Most health 
services employ health-care workers who can promote 
dietary improvement in a way similar to that used in this 
Mean (SD) Between-group 
diﬀ erences at 
6 months (95% CI)*
p Between-group 
diﬀ erences at 
12 months (95% CI)*
p
Baseline 6 months 12 months
(Continued from previous page)
Activity
Activity (counts per min)
Usual care 282 (129) 265 (127) 276 (160) ·· ·· ·· ··
Diet 280 (113) 284 (127) 277 (128) ·· ·· ·· ··
Diet and activity 266 (99) 312 (132) 299 (130) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 38·34 (18·8 to 57·9) 0·0001 31·98 (11·35 to 52·62) 0·002
Diet vs usual care ·· ·· ·· 8·00 (–17·9 to 33·9) 0·54 3·36 (–24·38 to 31·10) 0·81
Diet and activity vs usual care ·· ·· ·· 46·34 (20·0 to 72·7) 0·001 35·34 (7·35 to 63·34) 0·013
Time sedentary (min per day)
Usual care 536 (94) 542 (89) 536 (105) ·· ·· ·· ··
Diet 549 (77) 549 (87) 546 (93) ·· ·· ·· ··
Diet and activity 549 (86) 532 (91) 537 (82) ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· –21·79 (–37·04 to –6·54) 0·005 –4·58 (–20·45 to 11·30) 0·57
Diet vs usual care ·· ·· ·· 7·46 (–12·90 to 27·82) 0·47 0·31 (–21·56 to 22·18) 0·98
Diet and activity vs usual care ·· ·· ·· –14·44 (–35·03 to 6·36) 0·17 –4·27 (–26·24 to 17·70) 0·70
HOMA-B=homoeostasis model assessment for β-cell function. BMI=body-mass index. *Adjusted for male or female sex, route into study (general practice, education centre, 
or responding to an advertisement), age (continuous), ﬁ tness (low [if  maximum oxygen consumption poor or very poor on normative data] or high [if  maximum oxygen 
consumption fair, good, excellent, or superior on normative data]), study centre (Taunton, North Bristol, South Bristol, or Cheltenham and Gloucester), baseline glycated 
haemoglobin A1c (continuous), and blood pressure (<120/80 mm Hg, 120/80–139/89 mm Hg, or ≥140/90 mm Hg).
Table 5: Additional secondary outcomes at 6 and 12 months
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study, whereas fewer are trained to promote behaviour 
change for physical activity. These ﬁ ndings suggest that 
intervention at this early stage should focus on improving 
diet, since the additional cost of training health-care 
workers to promote activity might not be justiﬁ ed.
Few studies, all with small numbers, have been done 
in an attempt to discover whether changes to diet and 
activity are better than changes to diet alone in patients 
with type 2 diabetes. Three studies showed no 
improvements in HbA1c concentrations, weight, blood 
pressure, or insulin resistance with interventions 
involving exercise compared with those involving diet 
alone.11,12,14 One study showed an improvement in HbA1c 
concentrations9 and two studies showed better weight 
loss and glucose control when a walking programme 
was added to a diet intervention.10,13 All these studies, 
however, lacked power, were of short durations, and 
used no objective measurements of physical activity. 
Self-reporting of physical activity is inaccurate and, 
therefore, any eﬀ ects of exercise additional to those of 
diet intervention are diﬃ  cult to assess. We aimed to 
clarify this issue.
We were surprised to ﬁ nd no diﬀ erence between the 
intensive diet and intensive diet plus activity groups, 
particularly as a systematic review has previously shown 
a beneﬁ t of adding exercise to dietary intervention in 
obese participants.23,24 Objective measures conﬁ rmed that 
the amount of time spent in moderate to vigorous activity 
increased among patients in the intensive diet and 
activity group (table 3) in line with increases seen in 
Finnish and US diabetes prevention studies.25,26 No 
change in activity was seen in the other two study groups 
(table 3).
Changes in dietary behaviours are diﬃ  cult to monitor 
objectively, but the weight loss seen with both study 
interventions at 12 months, was similar to that reported 
with weight-loss medication,27 which suggests that notable 
changes were made. Dietary change was associated with 
real beneﬁ ts in waist circumferences and bioimpedance 
(table 3 and table 5). Additionally, glycaemic control and 
insulin resistance did not worsen in the two intervention 
groups, unlike in the control group (table 2 and table 3). 
Thus, the increase in use of diabetes medications at 
12 months in the intervention groups was only around a 
third of that required in the usual care group (table 6). 
The improvement in HbA1c concentrations associated 
with the intensive diet intervention, with and without 
activity, compares favourably with the HbA1c-lowering 
eﬀ ects of sitagliptin and metformin in treatment-naive 
patients with type 2 diabetes.28
Proportion of patients taking medication (%) Odds ratio (95% CI)* 
at 6 months
p Odds ratio (95% CI)* 
at 12 months
p
Baseline 6 months 12 months
Diabetes medication
Usual care 35·4 34·3 44·4 ·· ·· ·· ··
Diet 39·5 39·9 42·7 ·· ·· ·· ··
Diet and activity 38·6 39·4 42·3 ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 3·32 (0·23–48·87) 0·38 1·14 (0·50–2·62) 0·75
Diet vs usual care ·· ·· ·· 6·51 (0·23–188·38) 0·28 0·35 (0·12–0·96) 0·042
Diet and activity vs usual care ·· ·· ·· 21·64 (0·42–1117·93) 0·13 0·40 (0·14–1·09) 0·072
Blood pressure medication
Usual care 58·6 62·6 65·7 ·· ·· ·· ··
Diet 67·7 67·7 70·2 ·· ·· ·· ··
Diet and activity 56·2 59·4 63·8 ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 2·16 (0·51–9·12) 0·30 2·06 (0·81–5·22) 0·13
Diet vs usual care ·· ·· ·· 0·26 (0·05–1·44) 0·12 0·51 (0·16–1·65) 0·26
Diet and activity vs usual care ·· ·· ·· 0·56 (0·12–2·56) 0·46 1·05 (0·36–3·04) 0·93
Lipid medication
Usual care 63·6 64·5 66·7 ·· ·· ·· ··
Diet 65·3 66·5 67·7 ·· ·· ·· ··
Diet and activity 61·0 62·6 66·3 ·· ·· ·· ··
Diet and activity vs diet ·· ·· ·· 1·32 (0·37–4·65) 0·67 1·77 (0·72–4·37) 0·21
Diet vs usual care ·· ·· ·· 0·98 (0·19–5·08) 0·98 0·90 (0·27–5·16) 0·87
Diet and activity vs usual care ·· ·· ·· 1·30 (0·24–6·94) 0·76 1·60 (0·50–5·16) 0·43
*Adjusted for male or female sex, route into study (general practice, education centre, or responding to an advertisement), age (continuous), ﬁ tness (low [if maximum oxygen 
consumption ranked poor or very poor on normative data] or high [if maximum oxygen consumption ranked fair, good, excellent, or superior on normative data]), study 
centre (Taunton, North Bristol, South Bristol, and Cheltenham and Gloucester), baseline glycated haemoglobin A1c (continuous), blood pressure (<120/80 mm Hg, 
120/80–139/89 mm Hg, >140/90 mm Hg), and medication use at baseline (continuous).
Table 6: Medication use at 6 and 12 months
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Several reasons might explain why no additional beneﬁ t 
was achieved with use of an activity programme. Activity 
undertaken might have been of insuﬃ  cient intensity or 
been the incorrect type. A review revealed that vigorous 
aerobic exercise improves reduction in HbA1c 
concentrations29 and a randomised, controlled trial 
showed that anaerobic plus aerobic activity was associated 
with better metabolic control than aerobic activity alone.30 
The timing of intervention could have been too early in 
the disease process to show additional response. This 
eﬀ ect is suggested by our ﬁ nding that the intensive diet 
intervention plus activity worked better than the intensive 
diet intervention alone in patients who had high baseline 
HbA1c concentrations, insulin resistance, and BMI values 
than in those with lower values. A ﬁ nal explanation could 
be that the modiﬁ cation of two behaviours simultaneously 
diluted the eﬀ ect of both. Qualitative interview results 
suggest that people use a trade-oﬀ  system in which they 
reward themselves for additional exercise with increased 
food intake.31
Strengths of this study include community-based 
recruitment, the targeting of newly diagnosed 
individuals, the matching of contact time for the two 
study interventions, and the use of motivation-based 
lifestyle programmes without direct supervision that 
could be transferred into primary care at little cost. 
Additionally, retention of participants was high, 
contamination of changes in lifestyle activity between 
the study groups was low, and strict protocols for 
medication were used. 
The Early ACTID trial shows clearly that intensive 
dietary support soon after the diagnosis of type 2 diabetes 
is beneﬁ cial. This degree of dietary input (6·5 h additional 
time across the 12 months of the study, consisting of 2 h 
with a dietitian and 4·5 h with a nurse) improved 
glycaemic control, weight loss, and reduced need for 
drug treatment compared with usual care. The additional 
activity programme did not further improve outcomes 
(panel). Our ﬁ ndings support the redesign of diabetes 
services to increase dietary management at an early stage. 
Because the intensive diet intervention was designed to 
be delivered by practice nurses with dietitian support, 
this approach could be translated into community-based 
services. Further research is needed to clarify whether 
diﬀ erent programmes or intensities of physical activity, 
longer interventions, or intervention at an earlier or later 
stage of diabetes will have beneﬁ ts additive to those of 
dietary modiﬁ cation, and whether other beneﬁ ts will 
become apparent with longer duration of follow-up.
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